Revolution Medicines, Inc.
RVMD
55 insider filings · Latest: Sep 29, 2026
Common Stock Transactions
| Txn Date | Accepted | Insider | Type | Shares | Avg Price | Value | Shares Owned | Filing |
|---|---|---|---|---|---|---|---|---|
| Sep 29, 2026 | Oct 1 10:00 PM | Alan B. SandlerChief Development Officer | Sale | 6,309 | $202.14 | $1.3M | 52,559(D) | View → |
| Sep 25, 2026 | Sep 29 10:00 PM | Jeff CisliniSVP & General Counsel | Sale | 765 | $207.32 | $158.6K | 51,776(D) | View → |
| Sep 29, 2026 | Sep 29 8:24 PM | ALAN SANDLER | Proposed Sale | 6,309 | $201.74 | $1.3M | — | View → |
| Sep 25, 2026 | Sep 28 10:00 PM | Anthony ManciniChief Global Commercialization Officer | Sale | 3,121 | $200.54 | $625.9K | 39,765(D) | View → |
| Sep 24, 2026 | Sep 28 10:00 PM | Anthony ManciniChief Global Commercialization Officer | Sale | 587 | $200.00 | $117.4K | 39,765(D) | View → |
| Sep 25, 2026 | Sep 25 8:17 PM | ANTHONY MANCINI | Proposed Sale | 9,363 | $199.86 | $1.9M | — | View → |
| Sep 22, 2026 | Sep 24 10:00 PM | Elizabeth M AndersonDirector | Sale | 10,143 | $193.04 | $2.0M | 4,333(D) | View → |
| Sep 24, 2026 | Sep 24 8:42 PM | ANTHONY MANCINI | Proposed Sale | 587 | $190.74 | $112.0K | — | View → |
| Sep 18, 2026 | Sep 22 10:00 PM | Anthony ManciniChief Global Commercialization Officer | Sale | 1,764 | $196.94 | $347.4K | 40,352(D) | View → |
| Sep 22, 2026 | Sep 22 8:13 PM | Elizabeth Anderson | Proposed Sale | 15,080 | $192.76 | $2.9M | — | View → |
| Sep 16, 2026 | Sep 18 10:06 PM | Alan B. SandlerChief Development Officer | Sale | 341 | $199.24 | $67.9K | 52,868(D) | View → |
| Sep 16, 2026 | Sep 18 10:05 PM | Anthony ManciniChief Global Commercialization Officer | Sale | 1,774 | $199.24 | $353.4K | 42,116(D) | View → |
| Sep 16, 2026 | Sep 18 10:04 PM | Stephen Michael KelseySenior Advisor to the Chief Executive Officer | Sale | 5,569 | $199.24 | $1.1M | 286,307(D) | View → |
| Sep 16, 2026 | Sep 18 10:03 PM | Margaret A HornChief Operating Officer | Sale | 4,967 | $199.24 | $989.6K | 149,680(D) | View → |
| Sep 16, 2026 | Sep 18 10:02 PM | Mark A GoldsmithDirector, President and Chief Executive Officer | Sale | 13,988 | $199.24 | $2.8M | 253,342(D) | View → |
| Sep 16, 2026 | Sep 18 10:01 PM | Jeff CisliniSVP & General Counsel | Sale | 3,366 | $199.24 | $670.6K | 52,541(D) | View → |
| Sep 16, 2026 | Sep 18 10:00 PM | Jack AndersChief Financial Officer | Sale | 4,053 | $199.24 | $807.5K | 119,216(D) | View → |
| Sep 18, 2026 | Sep 18 8:18 PM | ANTHONY MANCINI | Proposed Sale | 1,764 | $196.94 | $347.4K | — | View → |
| Sep 15, 2026 | Sep 15 10:11 PM | Sandler Alan B | Proposed Sale | 331 | $203.77 | $67.4K | — | View → |
| Sep 15, 2026 | Sep 15 10:10 PM | Mancini Anthony | Proposed Sale | 2,377 | $203.77 | $484.4K | — | View → |
Page 1 of 8
Next →
Stock Options & Derivatives
| Txn Date | Accepted | Insider | Type | Shares | Exercise Price | Shares Owned | Filing |
|---|---|---|---|---|---|---|---|
| Apr 27, 2026 | Apr 29 9:50 PM | Anthony ManciniChief Global Commercialization Officer | Option Exercise | 3,120 | $33.62 | 109,230(D) | View → |
| Apr 15, 2026 | Apr 17 11:26 PM | Mark A GoldsmithDirector, President and Chief Executive Officer | Option Exercise | 120,000 | $4.73 | 424,085(D) | View → |
| Mar 25, 2026 | Mar 27 12:04 AM | Anthony ManciniChief Global Commercialization Officer | Option Exercise | 37,450 | $33.62 | 112,350(D) | View → |
| Mar 1, 2026 | Mar 4 2:11 AM | Xiaolin WangEVP, Clinical Development | Grant/Award | 34,000 | $102.02 | 34,000(D) | View → |
| Mar 1, 2026 | Mar 4 2:10 AM | Lin WeiChief Medical Officer | Grant/Award | 34,000 | $102.02 | 34,000(D) | View → |
| Mar 1, 2026 | Mar 4 2:09 AM | Stephen Michael KelseyPresident, Research and Development | Grant/Award | 47,600 | $102.02 | 47,600(D) | View → |
| Mar 2, 2026 | Mar 4 2:09 AM | Mark A GoldsmithDirector, President and Chief Executive Officer | Option Exercise | 30,000 | $4.09 | 47,708(D) | View → |
| Mar 1, 2026 | Mar 4 2:09 AM | Mark A GoldsmithDirector, President and Chief Executive Officer | Grant/Award | 128,600 | $102.02 | 128,600(D) | View → |
| Mar 1, 2026 | Mar 4 2:08 AM | Margaret A HornChief Operating Officer | Grant/Award | 47,600 | $102.02 | 47,600(D) | View → |
| Mar 1, 2026 | Mar 4 2:08 AM | Jeff CisliniGeneral Counsel | Grant/Award | 32,500 | $102.02 | 32,500(D) | View → |
| Mar 1, 2026 | Mar 4 2:07 AM | Jack AndersChief Financial Officer | Grant/Award | 45,400 | $102.02 | 45,400(D) | View → |
| Feb 6, 2026 | Feb 10 10:30 PM | Mark A GoldsmithDirector, President and Chief Executive Officer | Option Exercise | 24,010 | $0.54 | 144,493(D) | View → |
← Previous
Page 2 of 2